From advocacy to austerity: The new role of the U.S. public sector in HIV drug development and access
| Autor: | Ryan Whitacre |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Civil society
Economic growth Databases Factual Anti-HIV Agents HIV Infections Health Services Accessibility Article 03 medical and health sciences 0302 clinical medicine Drug Development Acquired immunodeficiency syndrome (AIDS) Political science medicine Humans 030212 general & internal medicine Government spending Government Public Sector 030505 public health business.industry Public sector Public Health Environmental and Occupational Health medicine.disease United States Scholarship Austerity Expanded access 0305 other medical science business |
| Zdroj: | Glob Public Health |
| ISSN: | 1744-1706 1744-1692 |
| Popis: | Whereas advocacy was once the driving force for U.S. public support for HIV drug development and access, the nation’s response to the global epidemic is now shaped by austerity. Extending past scholarship about the role of advocates and governments in support of drug development and access around the world, in this article I identify key shifts in U.S. public sector support over the past 40 years. During the early years of the AIDS epidemic, the U.S. government and civil society expedited drug development for antiretroviral therapy (ART). After the turn of the century, a new wave of advocacy expanded access for ART, including to low- and middle-income countries through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). On the heels of these accomplishments, advocates and governments set an ambitious agenda to ‘End AIDS’ by 2030. However, progress toward this goal has been limited by a new era of austerity, as demonstrated by U.S. government spending on HIV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|